Phospho-MYPT1 (Thr853) Antibody - #AF5445

Fig. 3. Icariin treatment increased active RhoA in rASCs. (A) The active and total RhoA protein levels were determined by Western blot analysis on days 0, 1, 3, 5, 7 and 9. The densitometric analysis of active RhoA protein expression was normalized to total RhoA. (B) The p-MYPT1 and GAPDH protein levels were determined by Western blot analysis on days 0, 1, 3, 5, 7 and 9. The densitometric analysis of p-MYPT1 protein expression was normalized to GAPDH. Data are shown as mean  SD (n = 3) in three independent experiments. *P < 0.05 compared to 0 day group.

FIGURE 3 | ANGPTL8 activated JNK and ROCK signaling.(C, D) The levels of ROCK I, ROCK II, p-MYPT1 and MYPT1 in HTR-8/SVneo cells.

Figure 3 ANGPTL8 activated JNK and ROCK signaling. (A, B) The levels of p-JNK and JNK in HTR-8/SVneo cells with IR, overexpression or silence of ANGPTL8 or/and insulin stimulation. (C, D) The levels of ROCK I, ROCK II, p-MYPT1 and MYPT1 in HTR-8/SVneo cells. (E) Glucose consumption was determined in HTR-8/SVneo cells with ANGPTL8 knockdown, JNK agonist Anisomycin (1 μg/ml) or JNK antagonist SP600125 (20 μM), and insulin stimulation. (F) The levels of insulin signaling related molecules were determined in HTR-8/SVneo cells. (*p < 0.05, **p < 0.01, ns. no significance).

Figure 4. Effect of Ac-SDKP on col I, α-SMA and α-Ac-Tub in fibroblasts induced by Ang II. (a) The coexpression of α-SMA and α-Ac-Tub in fibroblasts induced by Ang II measured by immunofluorescence. Scale bar=50μm. (b) Effect of Ac-SDKP, valsartan (AT1 inhibitor), TCS HDAC6 20b (specific HDAC6 inhibitor), and Y-27632 (ROCK inhibitor) on fibroblasts measured by Western blot. Data presented as mean±SEM; N=4 independent experiments.

Fig. 4.| Depletion of RhoGDIα attenuated myofibroblast differentiation by suppression of RhoA/ROCK signalling. (A), Levels of RhoA and phospho-MYPT in MRC-5 cells with RhoGDIα knockdown were determined by western blotting (n = 3).